Drug Profile

ABS 201 - Absci

Alternative Names: ABS-201 - Absci

Latest Information Update: 07 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AbSci
Class Antibodies; Skin disorder therapies
Mechanism of Action Prolactin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Alopecia

Most Recent Events

13 May 2025 Pharmacokinetics data from preclinical studies in Alopecia released by Absci
13 May 2025 Absci plans a phase I/IIa trial for Alopecia in early 2026 (Parenteral)
03 Apr 2025 Preclinical trials in Alopecia in USA (SC) before April 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com